ALS is among the most destructive diseases affecting the nervous system. It targets nerve cells responsible for voluntary muscles, leading to progressive weakness that makes everyday tasks impossible. Since nerve cells seldom recover once destroyed, early detection has become a primary focus of medical research.
Researchers at the University of Miami believe they’ve discovered a vital clue within the blood. Their latest study indicates that alterations in a small set of blood proteins could serve as early warning signs of ALS, potentially revealing the disease long before any symptoms manifest.
This breakthrough could be especially beneficial for families with inherited ALS risk. Some individuals are aware of their genetic predisposition but have no way to predict when symptoms might start. Up until now, medical professionals had limited tools to guide such discussions.
The team examined blood samples from participants in the Pre-fALS study, which has tracked individuals with inherited ALS risk over nearly twenty years. These volunteers provided blood and health data while still healthy, creating a unique record of the period leading up to disease onset.
Employing advanced laboratory techniques, scientists analyzed over 5,000 proteins in the blood samples. They found that dozens of these proteins changed levels before the participants developed ALS or frontotemporal dementia, a related condition that can occur alongside ALS.
To identify the most reliable early indicators, the researchers utilized artificial intelligence to analyze various protein combinations. They concluded that a panel of 19 proteins offered the most accurate predictions across different timelines, helping estimate when symptoms might appear.
A key protein in this panel was neurofilament light chain, already associated with nerve damage in previous studies. When combined with other proteins, it helped create a comprehensive picture of disease progression that surpasses the usefulness of any single marker.
The findings were validated using data from the UK Biobank, which includes health information from a broader population. The consistent results from this larger dataset boosted confidence that this protein pattern could have widespread application beyond the initial study group.
This discovery comes at a crucial time, as preventive treatments are increasingly entering clinical trials. Researchers are currently investigating whether the drug tofersen can delay or prevent ALS if administered before symptoms emerge.
The ability to determine the optimal timing for treatment could significantly improve its effectiveness. In the future, clinicians might intervene while the nervous system remains largely healthy, rather than waiting for irreversible nerve damage to occur.
While this research marks a significant step forward in early ALS detection, it is not definitive. Larger studies and real-world testing are required before these blood tests can become routine in medical practice.
Nevertheless, the evidence strongly suggests that blood-based biomarkers could revolutionize how ALS is diagnosed and treated, shifting the focus from reactive management to proactive prevention.
If you’re interested in neurological health, consider exploring studies on how Vitamin B9 deficiency is linked to increased dementia risk, or how foods rich in flavonoids might help prevent cognitive decline. Recent research also highlights how cranberries could improve memory, and examines how alcohol, coffee, and tea consumption impact cognitive health.
Source: University of Miami.
